Drug Profile
EDN OL1
Alternative Names: EDN-OL1; OL-1Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Edunn Biotechnology
- Developer Edunn Biotechnology; National Center for Advancing Translational Sciences
- Class Antisense oligonucleotides
- Mechanism of Action Amyloid inhibitors; Amyloidogenic protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (IV)